DUSA Pharmaceuticals, Inc (NASDAQ:DUSA): Reports Q4 revenue $15.3M, consensus $13.84M. Net income for the three-month period ended December 31, 2011 includes a $0.1M loss from discontinued operations related to the Company’s decision to cease selling its non-PDT products, ClindaReach and Meted, effective December 31, 2011.
The shares closed at $5.80, up $1.15, or 24.73%, on the day. Its market capitalization is $142.97 million.
Keryx Biopharmaceuticals (NASDAQ:KERX): The credibility of Jeremy Richards, author of a Seeking Alpha story regarding Keryx (NASDAQ:KERX) and Aeterna Zentaris (NASDAQ:AEZS), is being questioned after statements in the article could not be verified by anyone at his purported investment firm, the drug companies and Seeking Alpha, The Street’s Adam Feuerstein writes.
The shares closed at $4.35, down $0.59, or 11.94%, on the day. Its market capitalization is $308.95 million.
Akorn, Inc. (NASDAQ:AKRX): Sees FY12 revenue $228M-$238M, consensus $247.17M. Sees FY12 tax provision $24M-$26M, adjusted EBITDA $88M-$93M, CapEx $15M-$20M.
The shares closed at $11.26, down $1.32, or 10.53%, on the day. Its market capitalization is $1.07 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY): Tekmira Pharmaceuticals (NASDAQ:TKMR) disclosed that it has responded to the patent infringement lawsuit filed on Jan. 17, 2012 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals (NASDAQ:ISIS) in the U.S. District Court of Massachusetts by filing a motion to dismiss, seeking to eliminate claims for lack of standing. Tekmira alleges in its motion that Alnylam is seeking to assert rights that it does not have.
The shares closed at $11.68, down $0.97, or 7.67%, on the day. Its market capitalization is $592.27 million.
Merck & Co., Inc. (NYSE:MRK), Abbott Laboratories (NYSE:ABT): Abbott announced that it will collaborate with Merck to evaluate the use of a FISH-based companion diagnostic test to aid in the development of a Merck investigational cancer therapy. FISH-based companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more or less likely to benefit from a particular therapy. Under terms of the agreement, Abbott will develop a test based on its proprietary FISH technology, intended to identify deletions of the TP53 gene in cancer patients. The Abbott FISH assay will be evaluated in clinical trials to help identify patients more likely to respond favorably to Merck’s investigational cancer therapy.
MRK shares closed at $37.44, down $1.01, or 2.63%, on the day. Its market capitalization is $113.97 billion. ABT shares closed at $56.35, down $0.93, or 1.62%, on the day. Its market capitalization is $88.60 billion.
Johnson & Johnson (NYSE:JNJ): Comments taken from Cowen Annual Health Care Conference .
The shares closed at $64.35, down $0.56, or 0.86%, on the day. Its market capitalization is $176.65 billion.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Stella Mariz at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com